Evidence map›Paper›PMID 41618353›Full record

Trial reportJournal of ovarian research2026

Comparative efficacy of human chorionic gonadotropin alone versus dual trigger for oocyte maturation in advanced maternal age using the antagonist protocol: a randomized controlled trial.

Isarin Thanaboonyawat, Kittidech Phukittiwarangkul, Pattraporn Chera-Aree, Pitak Laokirkkiat

Abstract readRandomized Controlled TrialComparative Study
In one paragraph

Trial report in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Isarin ThanaboonyawatInfertility and Reproductive Biology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Prannok Road, Bangkok Noi, Bangkok, 10700, Thailand.
Kittidech PhukittiwarangkulInfertility and Reproductive Biology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Prannok Road, Bangkok Noi, Bangkok, 10700, Thailand.
Pattraporn Chera-AreeInfertility and Reproductive Biology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Prannok Road, Bangkok Noi, Bangkok, 10700, Thailand. pattraporn.che@mahidol.ac.th.
Pitak LaokirkkiatInfertility and Reproductive Biology Unit, Department of Obstetrics and Gynecology, Faculty of Medicine, Siriraj Hospital, Mahidol University, 2 Prannok Road, Bangkok Noi, Bangkok, 10700, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe dual trigger, combining a gonadotropin-releasing hormone agonist with hCG, is reported to improve number of mature oocytes, and cumulative live birth rates. However, few studies have focused on advanced-aged women, and the relationship between follicle size and MII oocyte retrieval rates in this group remains unclear.

methodsThis randomized controlled trial enrolled 164 patients aged 35–42 years undergoing intracytoplasmic sperm injection (ICSI). Participants were randomized (1:1) to hCG-only or dual trigger. Final oocyte maturation was induced when ≥ 2 follicles reached 17 mm, with retrieval 35 h later. Oocytes were aspirated by follicle size (< 13 mm, 13–17 mm, > 17 mm). All mature oocytes underwent ICSI. Embryo transfer was performed in fresh or frozen-thawed cycles. The primary outcome was MII oocytes count; secondary outcomes were fertilization, implantation, pregnancy, live birth, and miscarriage rates.

resultsAmong 164 participants, 83 were in the hCG group and 81 in the dual trigger group. Baseline characteristics, ovarian response, and types and doses of stimulation medicines were statistically comparable. The mean number of MII oocytes was 6.07 ± 4.02 in the hCG group and 5.78 ± 3.62 in the dual trigger group (P = 0.62). Fertilization rates were similar between groups. Subgroup analysis by follicle size (< 13 mm, 13–17 mm, and > 17 mm) showed that follicles < 13 mm in the dual trigger group produced more mature oocytes and a significantly higher fertilization rate compared with hCG-only (40.71% vs. 32.65%, P = 0.08; 80.43% vs. 65.25%, P < 0.03). The implantation rate, chemical pregnancy rate, and clinical pregnancy rate were clinically higher in the dual trigger group (37.7% vs. 28.57%; 45.90% vs. 34.92%; 40.98% vs. 34.92%), although the differences were not statistically significant (P > 0.31, 0.27, 0.58, respectively). Ongoing pregnancy and live birth rates remained similar (P = 0.84).

conclusionIn advanced-aged patients, the dual trigger and hCG trigger protocols yielded comparable numbers of total oocytes and MII oocytes. However, subgroup analysis indicated that dual trigger may improve fertilization rates in smaller follicles. Although a trend toward higher chemical and clinical pregnancy rates was observed with dual trigger, ongoing pregnancy and live birth rates remained comparable between groups.

trial registrationThis study was registered with the Thai Clinical Trials Registry ( https://www.thaiclinicaltrials.org ) on 15 March 2022 under the registration number TCTR20220315002.

Indexed as

Chorionic GonadotropinOocytesOvulation InductionAdultAdvanced Maternal AgeEmbryo TransferFemaleGonadotropin-Releasing HormoneHumansOocyte RetrievalPregnancyPregnancy RateSperm Injections, IntracytoplasmicTreatment OutcomeChorionic GonadotropinGonadotropin-Releasing HormoneDual triggerFertilization ratehCG triggerLive birth rateMII numberOocyte numberPregnancy rate

Identifiers

PMID41618353
PMCPMC13037259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.